Nuvalent Inc (NUVL)
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General